RxDoctor Payments Data

Barry Balot, DO

Internal Medicine · Lindenhurst, NYNPI 1215997887

Payments from drug & device makers

$853in general payments, 2019–2025

Across 35 payments — averaging $24.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$164
  • Kowa Pharmaceuticals America, Inc.$109
  • Boston Scientific$98
  • AbbVie$93
  • Abbott$62
  • Amgen$60
  • plus $267 from 9 others

What the payments were for

  • Food & beverage$853100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$853 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$579,910
Medicare patients
782
Services billed
6,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban551$255,052
XtandiEnzalutamide27$190,465
XareltoRivaroxaban246$114,486
JanuviaSitagliptin Phosphate219$104,519
JardianceEmpagliflozin120$103,647
VumerityDiroximel Fumarate12$94,902
XifaxanRifaximin52$70,979
OzempicSemaglutide59$56,263
SantylCollagenase Clostridium Hist.94$40,179
TrulicityDulaglutide17$38,981
Breo ElliptaFluticasone/Vilanterol77$34,771
EntrestoSacubitril/Valsartan82$34,448
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$27,118
JanumetSitagliptin Phos/Metformin Hcl18$25,296
MounjaroTirzepatide12$23,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$255,052551 claims
Johnson & JohnsonXarelto, Procrit$24$136,044268 claims
Boehringer IngelheimJardiance, Tradjenta$53$120,602138 claims
Lilly USA, LLCTrulicity, Mounjaro$164$62,32229 claims
NovartisEntresto$14$34,44882 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Lindenhurst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →